Print Email

MASCC Antiemetic Guidelines©


MASCC/ESMO Antiemetic Guidelines 2013
© 2013 MASCC™  All rights reserved worldwide.
Organizing and Overall Meeting Chairs:
Richard J. Gralla, MD, Fausto Roila, MD, Maurizio Tonato, MD, Jørn Herstedt, MD

On behalf of the ESMO/MASCC Guidelines Working Group, the updated antiemetic guidelines have been published in the Annals of Oncology. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. F. Roila, J. Herrstedt, M. Aapro, R.J. Gralla, et al. , Annals of Oncology 21 (Supplement 5): v232 - v243, 2010

Antiemetic Publications
Antiemetic Guidelines 2010 of the MASCC Antiemetic Study Group

Courtesy of MASCC and Springer, the updated full text version of the MASCC/ESO Antiemetic Guidelines papers found in Supportive Care in Cancer, vol. 19, Supplement 1/March 2011. >>View Articles
The papers in this edition of Supportive Care in Cancer represent a detailed summary of the deliberations from the consensus guideline meeting which took place in Perugia, Italy in June 2009. Please refer to the PowerPoint guideline presentation for the most recent, and updated version of the MASCC/ESMO Antiemetic Guideline.


MASCC Endorsed Guideline Partnerships
Acute AINV Guideline
From the Pediatric Oncology Group of Ontario (POGO) 
Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients
The purpose of this guideline is to provide health care providers with an approach to the prevention of acute antineoplastic-induced nausea and vomiting (AINV) in children who are receiving antineoplastic medication. The scope is limited to the prevention of AINV in the acute phase (within 24 hours of administration of an antineoplastic agent).

icon Download the Guidelines:
For translation information please contact Anne Young at ayoung@mascc.org 

English - Updated January 2013
MASCC Guidelines-English  (alt PDF 1.1MB) 
MASCC Guidelines-English (PPT 760KB) 

Translations

Arabic Translation - updated June 2010
Translated by Bassam Estfan
MASCC Guidelines-Arabic  
(alt PDF 236 KB)

German Translation - Updated April 2011
Translation provided by ASORS.
MASCC Guidelines-German  (alt PDF 1.1MB) 
MASCC Guidelines-German (PPT 620KB)

Greek Translation - updated November 2010
Translated by Ourania Nicolatou-Galitis and Erofili Papadopoulou
MASCC_Guidelines-Greek 
(alt PDF 1.2MB) 
MASCC_Guidelines-Greek 
(PPS 712 KB)

Portuguese Translation - updated March 2011
MASCC_Guidelines-Portuguese - PDF (alt PDF 1.2 MB)
MASCC_Guidelines-Portuguese - PPT (PPT 780 KB)

Russian Translation - updated August 2011
Translated by Anton Snegovoy
MASCC_Guidelines-Russian 
(alt PDF 1.2 MB) 
MASCC_Guidelines-Russian 
(PPT 828 KB)

Serbian Translation - updated April 2013
Translated by Snezana Bosnjak, Jelena Dimitrijevic and Ana Vujovic
MASCC_Guidelines-Serbian 
(alt PDF 1.2 MB) 
MASCC_Guidelines-Serbian 
(PPT 780 KB)

Spanish Translation - updated August 2011
Translated by Alvaro Menendez
MASCC_Guidelines-Spanish 
(alt PDF 1.2 MB) 
MASCC_Guidelines-Spanish 
(PPT 780 KB)

Turkish Translation - updated August 2010
Translated by Ahmet Sezer, Ali Ayberk Besen, Huseyin Abali
MASCC_Guidelines-Turkish 
(alt PDF 2.4 MB) 
MASCC_Guidelines-Turkish 
(PPT 750 KB)

The following translations of the updated 2010 guidelines will be available soon. 

Italian Translation - translated December 7, 2005
Translated by Dr. Garassina
alt MASCC_Guidelines-Italian - PDF
MASCC_Guidelines-Italian - PPT

Japanese Translation - translated August, 2007
Thanks to Pfizer Japan for support of guideline translation.
alt MASCC_Guidelines-Japanese -PDF
MASCC_Guidelines-Japanese -PPT

Korean Translation - translated December, 2008
Thanks to Dr. Young Seon Hong for guideline translation.
alt MASCC Guidelines-Korean -PDF

Spanish Translation - translated December, 2005
alt MASCC_Guidelines-Spanish - PDF
MASCC_Guidelines-Spanish - PPT


 
powered by MemberClicks